Literature DB >> 1317700

Subacute idiopathic demyelinating polyradiculoneuropathy.

R Hughes1, E Sanders, S Hall, P Atkinson, A Colchester, P Payan.   

Abstract

Seven cases of subacute idiopathic demyelinating polyradiculoneuropathy had a monophasic illness characterized by progressive weakness of all four limbs that evolved during 4 to 8 weeks. Neurophysiological investigations implied demyelination in all seven cases. In two patients, sural nerve biopsy specimens that were taken showed macrophage-associated demyelination. All patients made substantial or complete recoveries with oral prednisolone (four cases) or without treatment (three cases). None of the patients required ventilation or had autonomic complications. These cases provide a link between the acute idiopathic demyelinating form of Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy.

Entities:  

Mesh:

Year:  1992        PMID: 1317700     DOI: 10.1001/archneur.1992.00530300044009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

3.  Epidemiology of peripheral neuropathy.

Authors:  C N Martyn; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

Review 4.  The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.

Authors:  Brian C Callaghan; Raymond S Price; Kevin S Chen; Eva L Feldman
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

Review 5.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

6.  Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy.

Authors:  S Kuwabara; K Ogawara; S Misawa; M Mori; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

7.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

Review 8.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Chronic inflammatory demyelinating polyneuropathy.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

10.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors:  M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.